

REPUBLIC HEALTHCARE LTD:
ONE WILL HAVE TO WAIT IN ORDER TO LEARN
HOW LONG THIS COMPANY WILL LAST

It has been attempted on quite a number of occasions in the Hongkong Special Administrative Region (HKSAR) of the People's Republic of China (PRC), but it always turned out to be one gigantic flop after another.

The facts seem to have been established – at least in the HKSAR: Medical doctors, when asked to work as a team with other medical doctors, especially over an extended period of time, find it difficult so to do.

As the proverb has proved, over and over again: '*Pride comes before a fall.*'

And, sad to relate, many doctors are excessively proud of themselves when they catch sight of their shingles, hanging outside their offices, announcing that these are of the offices of Doctor So-and-So.

Of course, in the Republic of Singapore, it may well be that doctors are akin to ordinary people, laymen, if one prefers to call such homo sapiens.

TARGET () finds this suggestion difficult to swallow, however.

The Initial Public Offering (IPO) Of Republic Healthcare Ltd

Republic Healthcare Ltd (Code: 8357, The **G**rowth **E**nterprise **M**arket [the **GEM**], The Stock Exchange of

Hongkong Ltd) published and disseminated its Share Offer Prospectus on June 1, 2018.

The Company Offered a total of 130 million, one-cent Shares at the Indicative Offer Price Per Share, ranging from a low of 50 cents to a high of 60 cents.

Investors of the HKSAR were encouraged to subscribe to 13 million Offered Shares (the Public Offer tranche) and International Investors – Institutional Investors, Professional Investors in equities as well as Well-Heeled Investors – were singled out in order to seduce them to subscribe for some of the 117 million Offered Shares via select Share Placements (the Placing Share tranche).

On June 14, 2018, Management announced that the Offer Price Per Share had been struck at 60 cents – that highest level of the Indicative Offer Price Per Share range.

Management said that it anticipated, netting about \$HK53 million from the IPO.

The Offer Price and Allotment Results Announcement of June 14 stated, at Page Eight, Management's present thinking as to how the net proceeds would, most likely, be allocated:

1. Approximately, \$S2.60 million, that is about 28.50 percent, '*will be used to strategically expand and strengthen the network of the Group's DTAP (Dr Tan and Partners) Clinics*';
2. Approximately, \$S1.40 million, that is about 15.70 percent, '*will be used to establish new SA (aesthetics) Clinics*';
3. Approximately, \$S4.30 million, that is about 46.90 percent, '*will be used for continuing to attract and retain a talent pool of doctor and staff*';
4. Approximately, \$S0.60 million, that is about 6.40 percent, '*will be used to upgrade and improve the Group's information technology infrastructure and systems*';
5. Approximately, \$S0.10 million, that is about 1.10 percent, '*will be used to set up a centralised pharmacy*'; and,
6. Approximately, ... [CLICK TO ORDER FULL ARTICLE](#)

While TARGET makes every attempt to ensure accuracy of all data published, TARGET cannot be held responsible for any errors and/or omissions.

*If readers feel that they would like to voice their opinions about that which they have read in **TARGET**, please feel free to e-mail your views to editor@targetnewspapers.com. **TARGET** does not guarantee to publish readers' views, but reserves the right so to do subject to the laws of libel.*